Literature DB >> 10435568

Aberrant esophageal HLA-DR expression in a high percentage of patients with Crohn's disease.

G Oberhuber1, A Püspök, M Peck-Radosavlevic, M Kutilek, A Lamprecht, A Chott, H Vogelsang, M Stolte.   

Abstract

Esophageal histology is not well studied in patients with Crohn's disease (CD). We, therefore, analyzed the histologic and immunohistologic appearance of esophageal mucosa in CD. Biopsy specimens taken from the esophagus of 57 consecutive patients with known CD of the large and/or small bowel, of 200 Crohn's-free controls, of 15 cases with ulcerative colitis, and of 5 cases with viral esophagitis were evaluated. In controls, most patients had either HLA-DR negative esophageal epithelium or showed focal or diffuse basal staining. HLA-DR expression of all epithelial layers (transepithelial staining) was observed in only four (2%) control subjects, in one case with herpes esophagitis, but not in patients with ulcerative colitis. In contrast, transepithelial HLA-DR expression was found in 19 (33%) patients with CD (p < 0.0001). In CD patients, it was associated with a significantly increased epithelial content in T-cells (CD3+, TIA-1+, granzyme B+), B-cells (CD79a+), natural killer cells (CD57+), and macrophages (CD68+). There was no correlation with either histological findings elsewhere in the upper gastrointestinal tract or with laboratory findings, symptoms, CDAI, or medication. Transepithelial esophageal HLA-DR expression is common in CD. Immunohistochemistry may prove useful in supporting the histologic diagnosis of CD in staging procedures, for initial diagnosis as well as in doubtful cases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435568     DOI: 10.1097/00000478-199908000-00016

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Antigen presentation and MHC class II expression by human esophageal epithelial cells: role in eosinophilic esophagitis.

Authors:  Daniel J Mulder; Aman Pooni; Nanette Mak; David J Hurlbut; Sameh Basta; Christopher J Justinich
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Proliferation of T-cell subsets that contact tumour cells in colorectal cancer.

Authors:  S J C Golby; C Chinyama; J Spencer
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 3.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

4.  Loss of human leucocyte antigen class I and gain of class II expression are early events in carcinogenesis: clues from a study of Barrett's oesophagus.

Authors:  S Rajendra; R Ackroyd; N Karim; C Mohan; J J Ho; M K Kutty
Journal:  J Clin Pathol       Date:  2006-02-07       Impact factor: 3.411

5.  An alternative flow cytometry strategy for peripheral blood dendritic cell enumeration in the setting of repetitive GM-CSF dosing.

Authors:  Kehui Wang; Kevin P Nishimoto; Rita S Mehta; Edward L Nelson
Journal:  J Transl Med       Date:  2006-04-24       Impact factor: 5.531

6.  Aberrant HLA-DR expression in the conjunctival epithelium after autologous serum treatment in patients with graft-versus-host disease or Sjögren's syndrome.

Authors:  Katerina Jirsova; Petra Seidler Stangova; Michalis Palos; Gabriela Mahelkova; Sarka Kalasova; Ivana Rybickova; Tor Paaske Utheim; Viera Vesela
Journal:  PLoS One       Date:  2020-04-21       Impact factor: 3.240

7.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01

Review 8.  Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma.

Authors:  Wendy Anne Boivin; Dawn Michelle Cooper; Paul Ryan Hiebert; David James Granville
Journal:  Lab Invest       Date:  2009-09-21       Impact factor: 5.502

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.